RecruitingNot ApplicableNCT07166120

Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients

Sponsor

Washington University School of Medicine

Enrollment

112 participants

Start Date

Sep 11, 2025

Study Type

INTERVENTIONAL

Conditions

Smoking Smoking Cessation Physician's Role

Summary

This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.

Eligibility

Min Age: 18 YearsMax Age: 89 Years

Inclusion Criteria9

Eligibility Criteria for Clinicians:
Clinician from participating oncology/hematology clinic
At least 18 years of age
Can speak and understand English
Patient at participating clinic
Age 18-89 years
Current smoking (average cigarettes per day ≥5)
Can speak and understand English
Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion Criteria4

Active use of smoking cessation medication (within the past 30 days)
Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)
Patients who were deemed by the investigator to be ineligible for participation in the trial

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALUsual care

Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).

BEHAVIORALPrecision treatment

Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information, adapted for oncology.